Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fentanyl Transdermal System (JNJ-35685-AAA-G021) vs DURAGESIC in Healthy Subjects
NCT02617758Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2015
- Primary completion
- Jun 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fentanyl in chronic pain (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Time to Reach Maximum Plasma Concentration and 3 more. Started Nov 2015; status: completed.
02
Drugs
fentanyl
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT02617758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02617758.